학술논문
IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis.
Document Type
Article
Author
Maintz, Laura; Welchowski, Thomas; Herrmann, Nadine; Brauer, Juliette; Traidl‐Hoffmann, Claudia; Havenith, Regina; Müller, Svenja; Rhyner, Claudio; Dreher, Anita; Schmid, Matthias; Bieber, Thomas; Schmid‐Grendelmeier, Peter; Akdis, Cezmi; Lauener, Roger; Brüggen, Marie‐Charlotte; Bersuch, Eugen; Neumann, Avidan; Hammel, Gertrud; Renner, Ellen D.; Luschkova, Daria
Source
Subject
*ATOPIC dermatitis
*PERIOSTIN
*SKIN inflammation
*ALLERGIC rhinitis
*MACHINE learning
*
*
*
*
Language
ISSN
0105-4538
Abstract
Background: The heterogeneous (endo)phenotypes of atopic dermatitis (AD) require precision medicine. Currently, systemic therapy is recommended to patients with an Eczema Area and Severity Index (EASI) ≥ 16. Previous studies have demonstrated an improved treatment response to the anti‐interleukin (IL)‐13 antibody tralokinumab in AD subgroups with elevated levels of the IL‐13‐related biomarkers dipeptidyl‐peptidase (DPP)‐4 and periostin. Methods: Herein, 373 AD patients aged ≥12 years were stratified by IL‐13high, periostinhigh and DPP‐4high endotypes using cross‐sectional data from the ProRaD cohort Bonn. "High" was defined as >80th quantile of 47 non‐atopic controls. We analyzed endotype‐phenotype associations using machine‐learning gradient boosting compared to logistic regression. Results: Atopic dermatitis severity and eosinophils correlated with IL‐13 and periostin levels. Correlations of IL‐13 with EASI were stronger in patients with increased (rs = 0.482) than with normal (rs = 0.342) periostin levels. We identified eosinophilia >6% and an EASI range of 5.5–17 dependent on the biomarker combination to be associated with increasing probabilities of biomarkerhigh endotypes. Also patients with mild‐to‐low‐moderate severity (EASI < 16) featured increased biomarkers (IL‐13high: 41%, periostinhigh: 48.4%, DPP‐4high: 22.3%). Herthoge sign (adjusted Odds Ratio (aOR) = 1.89, 95% Confidence Interval (CI) [1.14–3.14]) and maternal allergic rhinitis (aOR = 2.79–4.47) increased the probability of an IL‐13high‐endotype, "dirty neck" (aOR = 2.83 [1.32–6.07]), orbital darkening (aOR = 2.43 [1.08–5.50]), keratosis pilaris (aOR = 2.21 [1.1–4.42]) and perleche (aOR = 3.44 [1.72–6.86]) of a DPP‐4high‐endotype. Conclusions: A substantial proportion of patients with EASI < 16 featured high biomarker levels suggesting systemic impact of skin inflammation already below the current cut‐off for systemic therapy. Our findings facilitate the identification of patients with distinct endotypes potentially linked to response to IL‐13‐targeted therapy. [ABSTRACT FROM AUTHOR]